Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis

Musa Sami; Amanda Worker; Marco Colizzi; Luciano Annibale; Debasis Das; Marlene Kelbrick; Savitha Eranti; Tracy Collier; Chidimma Onyejiaka; Aisling O'Neill; David Lythgoe; Philip McGuire; Steve C.R. Williams; Matthew Kempton; Sagnik Bhattacharyya

doi:10.1038/s41398-020-0790-1

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis

Musa Sami, Amanda Worker, Marco Colizzi, Luciano Annibale, Debasis Das, Marlene Kelbrick, Savitha Eranti, Tracy Collier, Chidimma Onyejiaka, Aisling O'Neill, David Lythgoe, Philip McGuire, Steve C.R. Williams, Matthew Kempton, Sagnik Bhattacharyya

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early Psychosis with minimal cannabis use (EPMC = 25); Controls with a history of cannabis use (HCC = 16) and Controls with minimal use (HCMC = 22). Whole brain T1 weighted MR images and localised proton MR spectra were acquired from head of caudate, anterior cingulate and hippocampus. We examined relationships in regions with known high cannabinoid 1 receptor (CB1R) expression (grey matter, cortex, hippocampus, amygdala) and low expression (white matter, ventricles, brainstem) to caudate Glutamine+Glutamate (Glx). Patients were well matched in symptoms, function and medication. There was no significant group difference in Glx in any region. In EPC grey matter volume explained 31.9% of the variance of caudate Glx (p = 0.003) and amygdala volume explained 36.9% (p = 0.001) of caudate Glx. There was no significant relationship in EPMC. The EPC vs EPMC interaction was significant (p = 0.042). There was no such relationship in control regions. These results are the first to demonstrate association of grey matter volume and striatal glutamate in the EPC group. This may suggest a history of cannabis use leads to a conformational change in distal CB1 rich grey matter regions to influence striatal glutamatergic levels or that such connectivity predisposes to heavy cannabis use.

Original language	English
Article number	111
Journal	Translational psychiatry
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41398-020-0790-1
Publication status	Published - 1 Dec 2020

Access to Document

10.1038/s41398-020-0790-1Licence: CC BY

Fingerprint

Dive into the research topics of 'Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis'. Together they form a unique fingerprint.

Cite this

Sami, M., Worker, A., Colizzi, M., Annibale, L., Das, D., Kelbrick, M., Eranti, S., Collier, T., Onyejiaka, C., O'Neill, A., Lythgoe, D., McGuire, P., Williams, S. C. R., Kempton, M., & Bhattacharyya, S. (2020). Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis. Translational psychiatry, 10(1), [111]. https://doi.org/10.1038/s41398-020-0790-1

@article{d3678a42ad63497c90a4d2c38ff66676,

title = "Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis",

abstract = "The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early Psychosis with minimal cannabis use (EPMC = 25); Controls with a history of cannabis use (HCC = 16) and Controls with minimal use (HCMC = 22). Whole brain T1 weighted MR images and localised proton MR spectra were acquired from head of caudate, anterior cingulate and hippocampus. We examined relationships in regions with known high cannabinoid 1 receptor (CB1R) expression (grey matter, cortex, hippocampus, amygdala) and low expression (white matter, ventricles, brainstem) to caudate Glutamine+Glutamate (Glx). Patients were well matched in symptoms, function and medication. There was no significant group difference in Glx in any region. In EPC grey matter volume explained 31.9% of the variance of caudate Glx (p = 0.003) and amygdala volume explained 36.9% (p = 0.001) of caudate Glx. There was no significant relationship in EPMC. The EPC vs EPMC interaction was significant (p = 0.042). There was no such relationship in control regions. These results are the first to demonstrate association of grey matter volume and striatal glutamate in the EPC group. This may suggest a history of cannabis use leads to a conformational change in distal CB1 rich grey matter regions to influence striatal glutamatergic levels or that such connectivity predisposes to heavy cannabis use.",

author = "Musa Sami and Amanda Worker and Marco Colizzi and Luciano Annibale and Debasis Das and Marlene Kelbrick and Savitha Eranti and Tracy Collier and Chidimma Onyejiaka and Aisling O'Neill and David Lythgoe and Philip McGuire and Williams, {Steve C.R.} and Matthew Kempton and Sagnik Bhattacharyya",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41398-020-0790-1",

language = "English",

volume = "10",

journal = "Translational psychiatry",

issn = "2158-3188",

publisher = "Nature Publishing Group",

number = "1",

}

Sami, M , Worker, A , Colizzi, M, Annibale, L, Das, D, Kelbrick, M, Eranti, S , Collier, T, Onyejiaka, C, O'Neill, A , Lythgoe, D , McGuire, P , Williams, SCR , Kempton, M & Bhattacharyya, S 2020, 'Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis', Translational psychiatry, vol. 10, no. 1, 111. https://doi.org/10.1038/s41398-020-0790-1

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis. / Sami, Musa ; Worker, Amanda ; Colizzi, Marco et al.
In: Translational psychiatry, Vol. 10, No. 1, 111, 01.12.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Association of cannabis with glutamatergic levels in patients with early psychosis

T2 - Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis

AU - Sami, Musa

AU - Worker, Amanda

AU - Colizzi, Marco

AU - Annibale, Luciano

AU - Das, Debasis

AU - Kelbrick, Marlene

AU - Eranti, Savitha

AU - Collier, Tracy

AU - Onyejiaka, Chidimma

AU - O'Neill, Aisling

AU - Lythgoe, David

AU - McGuire, Philip

AU - Williams, Steve C.R.

AU - Kempton, Matthew

AU - Bhattacharyya, Sagnik

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early Psychosis with minimal cannabis use (EPMC = 25); Controls with a history of cannabis use (HCC = 16) and Controls with minimal use (HCMC = 22). Whole brain T1 weighted MR images and localised proton MR spectra were acquired from head of caudate, anterior cingulate and hippocampus. We examined relationships in regions with known high cannabinoid 1 receptor (CB1R) expression (grey matter, cortex, hippocampus, amygdala) and low expression (white matter, ventricles, brainstem) to caudate Glutamine+Glutamate (Glx). Patients were well matched in symptoms, function and medication. There was no significant group difference in Glx in any region. In EPC grey matter volume explained 31.9% of the variance of caudate Glx (p = 0.003) and amygdala volume explained 36.9% (p = 0.001) of caudate Glx. There was no significant relationship in EPMC. The EPC vs EPMC interaction was significant (p = 0.042). There was no such relationship in control regions. These results are the first to demonstrate association of grey matter volume and striatal glutamate in the EPC group. This may suggest a history of cannabis use leads to a conformational change in distal CB1 rich grey matter regions to influence striatal glutamatergic levels or that such connectivity predisposes to heavy cannabis use.

AB - The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early Psychosis with minimal cannabis use (EPMC = 25); Controls with a history of cannabis use (HCC = 16) and Controls with minimal use (HCMC = 22). Whole brain T1 weighted MR images and localised proton MR spectra were acquired from head of caudate, anterior cingulate and hippocampus. We examined relationships in regions with known high cannabinoid 1 receptor (CB1R) expression (grey matter, cortex, hippocampus, amygdala) and low expression (white matter, ventricles, brainstem) to caudate Glutamine+Glutamate (Glx). Patients were well matched in symptoms, function and medication. There was no significant group difference in Glx in any region. In EPC grey matter volume explained 31.9% of the variance of caudate Glx (p = 0.003) and amygdala volume explained 36.9% (p = 0.001) of caudate Glx. There was no significant relationship in EPMC. The EPC vs EPMC interaction was significant (p = 0.042). There was no such relationship in control regions. These results are the first to demonstrate association of grey matter volume and striatal glutamate in the EPC group. This may suggest a history of cannabis use leads to a conformational change in distal CB1 rich grey matter regions to influence striatal glutamatergic levels or that such connectivity predisposes to heavy cannabis use.

UR - http://www.scopus.com/inward/record.url?scp=85083772556&partnerID=8YFLogxK

U2 - 10.1038/s41398-020-0790-1

DO - 10.1038/s41398-020-0790-1

M3 - Article

SN - 2158-3188

VL - 10

JO - Translational psychiatry

JF - Translational psychiatry

IS - 1

M1 - 111

ER -

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for Altered Volume Striatal Glutamate Relationships in patients with a history of cannabis use in Early Psychosis

Abstract

Access to Document

Other files and links

Embargoed Document

Fingerprint

Cite this